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Summary Two hundred patients with node positive stage II breast cancer were randomised to four groups
after radical mastectomy and axillary evacuation: (1) Postoperative radiotherapy, (2) Adjuvant chemotherapy
with eight courses of CAFt (cyclophosphamide 500 mg m-2 + doxorubicin 40 mg/m-2 + ftorafur 20 mg kg-'
orally day 1-14) every fourth week, (3) Postoperative radiotherapy and adjuvant chemotherapy and (4)
postoperative radiation, adjuvant chemotherapy and tamoxifen 40 mg daily for 2 years.
Thirty-two per cent of the patients discontinued treatment due to GI-toxicity, while 26% required dose
reductions due to leukopenia. Radiation pneumonitis was more frequent after the combination of postopera-
tive radiotherapy with chemotherapy. There was a better relapse-free survival in the groups receiving
chemotherapy compared to radiotherapy alone (P = 0.05), which was highly significant in a multivariate Cox
analysis (P = 0.004). No significant survival differences were seen. Tamoxifen had no clear overall effect but
there were better relapse-free (P = 0.04) and overall (P = 0.004) survival with tamoxifen in estrogen receptor
positive patients, while estrogen receptor negative patients had a somewhat poorer survival (P = 0.07) after
tamoxifen.
Local control was better (NS) after the combination (93%) radiotherapy and chemotherapy compared to
either treatment alone (76% with radiotherapy and 74% with chemotherapy at 5 years).
The ability of adjuvant treatment to improve the prognosis in
primary breast cancer has during the last two decades been
demonstrated in numerous clinical trials. In the 1985 statis-
tical overview of randomised trials in primary breast cancer
by the Early Breast Cancer Trialists Group adjuvant chemo-
therapy was found to improve overall and disease-free sur-
vival in node-positive breast cancer in women younger than
50 years at diagnosis and adjuvant tamoxifen in women older
than 50 years (EBCTCG, 1988; EBCTCG, 1990). In a new
overview analysis published in the Lancet in January 1992
these treatment effects were found to persist at least 10 years
from randomisation (EBCTCG, 1992). Furthermore, evi-
dence was obtained of an independent favourable effects of
chemotherapy either alone or in combination with tamoxifen
on mortality in postmenopausal women aged 50-69, while
the effects of chemohormonal treatment in premenopausal
patients could not be estimated reliably (EBCTCG, 1992).
Tamoxifen alone was, however, found to reduce recurrence
(P<0.001) in women below 50 years of age, although the
effect was significantly less than in older women.
In a recent overview study postoperative radiotherapy was
found not to improve overall survival in primary breast
cancer, survival was in fact somewhat shortened by radio-
therapy after more than 10 years of follow-up (Cuzick et al.,
1987). In a subsequent report on one of the largest trials in
the overview, the CRC trial, the excess mortality was found
to be due to an increased mortality from cardiovascular
causes and second neoplasms. More recent results have, how-
ever, challenged the general conclusion of the radiotherapy
overview (H0st & Brennhovd, 1977; Mouridsen & Over-
gaard, 1990; Rutqvist et al., 1990). In a controlled trial
conducted in Stockholm postoperative radiotherapy was
found to significantly improve both relapse-free survival and
diminish the occurrence of distant metastases in patients with
axillary lymph node metastases (Rutqvist et al., 1990). In
another trial conducted in Oslo a significantly improved sur-
vival (P<0.05) was also found in patients with stage II
primaries treated with a cobolt source, while no improvement
was seen with ortho-voltage treatment (H0st & Brennhovd,
1977). In two large trials by the Danish Breast Cancer Group
the effect of postoperative radiation added to adjuvant was
investigated (Dombernowsky et al., 1988; Mouridsen et al.,
1988). It was found that adjuvant therapy alone was unable
to prevent the occurrence of local recurrences, which were
significantly reduced by postoperative radiotherapy (Domber-
nowsky et al., 1988; Mouridsen et al., 1988). In premenopau-
sal patients the addition of postoperative radiation resulted
in a small but statistically significantly improved overall sur-
vival (Mouridsen & Overgaard, 1990).
Although doxorubicin (dox) is one of the most effective
agents in metastatic breast cancer (Brincker, 1988) few ran-
domised studies have included this drug into adjuvant regi-
mens, possibly due to fear of long-term toxicity, especially
cardiotoxicity. Several retrospective as well as controlled
trials have, however, demonstrated the feasibility and low
long-term toxicity of dox containing adjuvant chemotherapy
(Buzdar et al., 1989; Fisher et al., 1990; Fisher et al., 1989;
Grohn et al., 1984; Morrison et al., 1989; Perloff et al., 1986;
Wendt et al., 1979). In one controlled trial by the NSABP
group dox was found to improve prognosis when added to
melphalan fluorouracil adjuvant treatment in tamoxifen-non-
responsive patients, while no effect of dox was found when
added to the same regimen plus tamoxifen in tamoxifen-
responsive patients (Fisher et al., 1989). In a previous study
in stage III breast cancer at this department adjuvant chemo-
therapy with the VAC regimen was found to significantly
diminish the occurrence of distant recurrence when added to
postoperative radiation (Grohn et al., 1984).
Several controlled trials have been investigating the role of
tamoxifen added to adjuvant chemotherapy in primary breast
cancer (Bianco et al., 1988; Fisher et al., 1986; Fisher et al.,
1981; Marshall et al., 1987; Mauriac et al., 1988; Tormey et
al., 1990). The results of these trials have been confficting,
most reporting a benefit of tamoxifen in receptor positive
patients (Bianco et al., 1988; Fisher et al., 1986; Fisher et al.,
1981; Marshall et al., 1987; Mauriac et al., 1988), while one
trial found evidence of benefit in receptor negative patients
only (Tormey et al., 1990). We here report the results after 6
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years of follow-up of a randomised trial comparing the
effects of combinations of radiotherapy, dox-based chemo-
therapy and tamoxifen as adjuvant treatment in node positive
stage II breast cancer.
Patients and methods
Between January 1981 and December 1984 200 consecutive
patients with stage II primary breast cancer in two Onco-
logical Departments [Department of Radiotherapy and
Oncology, University of Helsinki (n = 194) and Department
of Radiotherapy and Oncology, University of Tampere
(n = 5)] were included in the study. Eligible for the trial were
women with TI-2N1 breast cancer with histologically proven
axillary metastases. Exclusion criteria included age above 70,
severe cardiac disease and Karnofsky performance index
below 60%. One patient (in the CT + RT + Tam group) did
not fulfil the inclusion criteria, she had a stage III tumour of
7 cm diameter and was excluded from analysis. Staging inves-
tigations included clinical investigation, liver scintigraphy or
ultrasound, chest x-ray and bone scintigraphy. No stratifica-
tion according to menopausal status was done.
The patients were randomised into four groups:
(1) postoperative radiation (RT, n = 50),
(2) adjuvant chemotherapy (CT, n = 52),
(3) both postoperative radiation and chemotherapy (CT +
RT, n = 47),
(4) postoperative radiation, chemotherapy and adjuvant
tamoxifen (CT + RT + Tam, n = 50).
Six patients had protocol violations (one patient received
intravenous fluorouracil instead of oral ftorafur, one patient
in CT + RT + Tam group did not receive tamoxifen, two
patients in the RT group received adjuvant chemotherapy,
one CMF and the other CAF, one patient in the RT group
received adjuvant tamoxifen and one patient received adju-
vant CAFt instead of radiotherapy). These patients are
included in the analyses of treatment efficacy unless otherwise
specified but excluded from toxicity analysis.
Surgical treatment was modified radical mastectomy and
axillary evacuation in all cases. Operative technique was not
standardised.
Postoperative irradiation was given between the second
and third adjuvant chemotherapy cycles. Postoperative radia-
tion was given with a cobolt source 45 Gy in 15 fractions
from an oblique field to the operative area, and from anterior
fields to the supraclavicular, axillary and parasternal areas.
The mid-axillary dose was supplemented with 30 Gy in 10
fractions from a posterior axillary field. All doses are field
doses.
Adjuvant chemotherapy consisted of 8 four-weekly cycles
of cyclophosphamide, dox, ftorafur, an oral analogue of
fluorouracil. The dosage and schedule of adjuvant CAFt is
shown in Table I.
Adjuvant tamoxifen was given in a dosage of 40 mg daily
for 2 years.
Pretreatment characteristics of the patients in the four
groups is shown in Table II. The mean age of the patients
was 52 years. Estrogen and progesterone receptor values were
available in 166 patients 53% of which were estrogen recep-
tor positive and 48% of which progesterone receptor posi-
tive. Twenty-nine percent of the patients had more than three
axillary lymph nodes involved (Table II). The four treatment
groups were well balanced with respect to these pretreatment
characteristics. One patient discontinued follow-up after 4.7
Table I The CAFt regimen
Drug Dose Days
Cyclophosphamide 500mg m-2 i.v. 1
Doxorubicin 40mg m-2 i.v I
Ftorafur 20 mgkg-' p.o. 1-14
A new cycle starts on day 29.
Table II Pretreatment characteristics
n (%)
RT+ CT+
RT CT RT+ CT Tam P
Estrogen receptor
Positive 20 (40) 25 (48) 21 (45) 22 (44) 0.92
Negative 18 (36) 20 (39) 22 (47) 18 (36)
Unknown 12 (24) 7 (13) 4 (9) 10 (20)
Progesterone receptor
Positive 20 (40) 25 (48) 18 (38) 16 (32) 0.39
Negative 18 (36) 20 (39) 25 (53) 24 (48)
Unknown 12 (24) 7 (13) 4 (9) 10 (20)
Number of involved nodes
1-3 33 (66) 38 (73) 29 (62) 32 (64) 0.27
4 or more 16 (32) 9 (17) 16 (34) 17 (34)
Not assessed 1 (2) 5 (10) 2 (4) 1 (2)
Age
> 50 20 (40) 20 (39) 23 (49) 19 (38) 0.67
<50 30 (60) 32 (62) 24 (51) 31 (62)
years, otherwise all patients are followed for more than 5
years. Median follow-up time is 7.5 years.
White blood counts, differential, hemoglobin, and throm-
bocytes were investigated every second week in the patients
in the chemotherapy arms and ASAT, ALAT, 5-nucleotidase,
alkaline phosphatase, serum creatinine and blood electrolytes
monthly. After treatment the patients were followed at 3-4
months intervals for first 2 years and thereafter with 6
months interval at least 5 years. After the 5th year controls
were performed once a year. The follow-up included clinical
investigation, liver enzymes (ASAT, ALAT, 5-nucleotidase,
alkaline phosphatase) and serum creatinine. Chest x-ray were
performed at 3-6 month intervals during the first 5 years of
follow-up. Bone scan and liver ultrasound were performed 2
years after primary treatment and thereafter only at suspicion
of recurrence.
Statistical testing was done with the Chi-square test in
pairwise comparison of the frequency of occurrence of events,
with the Mann-Whitney test in comparison on toxicity grad-
ed according to the WHO-scale and with the log-rank test on
Kaplan-Meier estimates of overall and relapse-free survival
and time to local recurrence. Local recurrence was defined as
any ipsilateral chest-wall or nodal recurrence in the axillary
or supraclavicular area. In analysis of time to local recur-
rence the patient was considered censored if she died without
evidence of local disease. The effect of the three treatment
modalities (radiotherapy, chemotherapy and tamoxifen) on
relapse-free and overall survival was further tested with a
Cox stepwise multivariate analysis. No other factors were
included in this analysis. The effect of tamoxifen was also
studied in a separate Cox analysis with age, and receptor
status included in the model.
Results
Toxicity
Hematological toxicity WHO grade III and IV occurred in
none, 6%, 32% and 40% in the RT, CT, CT + RT and
CT + RT + Tam groups respectively. Hematological toxicity
was significantly worse in the CT compared to the radio-
therapy group (P = 0.0001), in the CT + RT group compared
to the CT group (P = 0.0001), while the difference between
the CT + RT and CT + RT + Tam groups was nonsignifi-
cant (P = 0.58, all P-values with the Mann-Whitney test).
Symptomatic radiation pneumonitis occurred in 4%, 23%
and 33% in the RT, RT + CT and RT + CT + Tam groups,
respectively. Pneumonitis developed significantly more often
in the RT + CT group compared to the RT group (P =
0.008, Chi-square). There was no significant difference in theSTAGE II BREAST CANCER ADJUVANT TRIAL 1173
occurrence of pneumonitis between the RT + CT and RT +
CT + Tam groups (P = 0.28, Chi-square). Nausea and alo-
pecia occurred in the majority of the patients in the chemo-
therapy groups, but data were not systematically registered.
One patient receiving radiotherapy, chemotherapy and tamo-
xifen experienced a (non-fatal) leukopenic sepsis probably of
urological origin, and one patient in the CT + RT group
developed a bacterial colitis during adjuvant chemotherapy
requiring hospitalisation. No other grade 3 or 4 infections
were noted. One case of cardiomyopathy developed in a
patient in the chemotherapy group 6 years after adjuvant
treatment. The patient responded to anticongestive medica-
tion and is still alive 10 years after primary treatment.
Twelve patiens in the CT (23%), 17 in the RT + CT (36%)
and 18 patients in the CT + RT + Tam group (38%) discon-
tinued their adjuvant treatment due to toxicity, most com-
monly intractable nausea and vomiting. One patient in the
RT + CT group discontinued both radiotherapy and chemo-
therapy because of colitis, otherwise none of the patients
discontinued radiotherapy. Dose-reductions of adjuvant
chemotherapy, most commonly due to hematological toxicity
was necessary in 9 (17%), 13 (28%) and 15 (31%) patients in
the CT, CT + RT and CT + RT + tamoxifen groups respec-
tively. The difference in the occurrence of dose-reductions
and discontinuation of chemotherapy between the CT and
CT + RT groups were not statistically significant (P = 0.22
and 0.15, respectively Chi-square test). Dose reduction and
discontinuation were observed with equal frequencies among
patients younger or older then 50 years.
Efficacy
Local recurrence rate, distant-disease-free, relapse-free and
overall survival in the four treatment groups is shown in
Table III.
Thirty-two patients developed local recurrences, only three
of them more than 5 years after primary operation. There
was no statistical significant difference between the four treat-
ment groups in local recurrence (P=0.12, log-rank test on
time to local recurrence, patients dead without local recur-
rence considered censored). The differences in local recur-
rence between the RT + CT and RT groups, the RT + CT
and CT groups and between the RT + CT and CT + RT +
Tam groups were not statistically significant (P = 0.08, 0.14
and 0.93, respectively, log-rank test). In a stepwise multi-
variate Cox-analysis none of the treatment modalities were
significantly associated to time to local recurrence (P = 0.29,
0.12 and 0.13, for radiotherapy, chemotherapy and tamox-
ifen, respectively).
There were no overall significant difference in distant-meta-
stasis-free survival between the four treatment groups (P =
0.10, log-rank test). The differences in distant recurrence-free
survival between the CT + RT and RT, CT + RT and CT,
and CT + RT + TAM and the CT + RT groups were non-
significant (P = 0.17, 0.49 and 0.54, respectively). In a multi-
variate Cox stepwise analysis adjuvant chemotherapy was the
only treatment variable significantly associated with distant
recurrence-free survival (P = 0.02), while the effect of radio-
therapy and tamoxifen were nonsignificant (both P = 0.26).
The difference in relapse-free survival in the four treatment
groups was statistically significant (Figure 1, P = 0.02, log-
rank test). The difference in relapse-free survival between
the CT + RT and RT groups was statistically significant
(P = 0.05), while the differences between the CT + RT and
CT and CT + RT and CT + RT + TAM groups were statis-
tically nonsignificant (P = 0.76 and 0.66, respectively). In the
stepwise Cox multivariate analysis adjuvant chemotherapy
was significantly correlated to relapse-free survival
(P = 0.004), while the effect of radiotherapy and tamoxifen
was nonsignificant (P = 0.30 and 0.19, respectively).
No significant difference in overall survival was found
between the four treatment groups (P = 0.34, log-rank test).
The survival differences between the RT + CT and RT,
RT + CT and CT, and RT + CT + Tam and RT + CT
groups were nonsignificant (P = 0.57, 0.69 and 0.54, respec-
tively). In the stepwise Cox multivariate analysis no treat-
ment factor gained statistical significance (P = 0.15, 0.16 and
0.70 for radiotherapy, adjuvant chemotherapy and tamox-
ifen, respectively).
No statistically significant effect ofadjuvant tamoxifen was
found on local or distant recurrence, relapse-free or overall
survival. In a Cox stepwise multivariate analysis including
estrogen and progesterone receptors and age at diagnosis
(age<50 or >50) tamoxifen adjuvant treatment had no
statistically effect on overall or relapse-free survival (P = 0.60
and 0.90, respectively) while the association of both the
estrogen and progesterone receptor status and overall (P=
0.09 and 0.07 for the estrogen and progesterone receptor,
respectively) or relapse-free (P = 0.09 and 0.06 for the estro-
gen and progesterone receptor, respectively) survival were
close to significance. No interaction between the effect of
tamoxifen on overall or relapse-free survival and age at
primary diagnosis was found (for survival P = 0.94 and 0.40
in patients younger than or older and equal to 50 years of
age and for relapse-free survival P = 0.95 and 0.41, respec-
tively). Estrogen receptor positive patients showed a statisti-
cally significantly improved relapse-free (P = 0.04) and over-
all survival (P = 0.004) with tamoxifen. Five years survival
was 71% and 95% without and with tamoxifen adjuvant
treatment in estrogen receptor positive patients. In patients
with estrogen receptor negative tumours on the other hand
recurrence-free (P = 0.08) and overall survival (P = 0.07)
seemed to be worse after tamoxifen. Five years survival was
68% without tamoxifen and 44% with tamoxifen adjuvant
treatment in estrogen receptor negative patients. No difference
between the CT + RT and CT + RT + Tam in the frequency
of dose-reductions and discontinuations of chemotherapy
was found in either the estrogen receptor positive (P = 0.83,
chi-square) or negative group (P = 0.36). There was no signi-
ficant effect of tamoxifen adjuvant therapy on overall or
relapse-free survival either in progesterone receptor positive
(P = 0.62 and 0.57, respectively) or negative (P = 0.63 and
0.60, respectively) patients. Of the 16 patients with estrogen
receptor positive and progesterone receptor negative patients
seven of nine in the RT + CT group have died, while none of
the seven patients in the CT + RT + Tam group died. Seven
patients (five in the RT + CT and two in the RT + CT +
Tam groups) were estrogen receptor negative progesterone
Table In Overall, relapse-free, distant relapse-free survival and local control
Distant relapse-free Local
Survival Relapse-free survival survival control
Group 5 year 8 year 5 year 8 year 5 year 8 year 5 year
CT 87% 69% 65% 56% 73% 59% 76%
RT 70% 55% 42% 36% 50% 41% 74%
CT+ RT 72% 65% 64% 56% 64% 54% 93%
CT + RT + TAM 74% 67% 66% 61% 68% 63% 91%1174 C. BLOMQVIST et al.
receptor positive. Only two of them have died, one in each
treatment group.
Discussion
Despite the high efficacy of dox in the metastatic setting
relatively few studies have addressed the use of dox-based
chemotherapy as adjuvant therapy in breast cancer. The
feasibility and low incidence of long-term toxicity of dox
combinations as adjuvant therapy has been demonstrated in
several uncontrolled studies (Abeloff et al., 1990; Budman et
al., 1990; Buzdar et al., 1989). A few controlled studies have
also evaluated the impact of dox or dox combination therapy
on prognosis (Fisher et al., 1990; Fisher et al., 1989; Grohn
et al., 1984; Morrison et al., 1989; Perloff et al., 1986). A
previous study at this department of the VAC combination
(vincristine-dox-cyclophosphamide) as adjuvant therapy in
stage III breast cancer demonstrated a significantly better
relapse free and overall survival with adjuvant chemotherapy
and radiotherapy compared to radiotherapy alone (Grohn et
al., 1984). In a West Midlands Oncology Association study
Morris et al. reported significantly improved relapse-free sur-
vival after AVCMF adjuvant therapy compared to controls
not given adjuvant chemo- or radiotherapy (Morrison et al.,
1989). In two NSABP studies, trial B-l1 and B-12, patients
considered 'tamoxifen-unresponsive' according to age and
receptor status were randomised to PF (Melphalan-5-
Fluorouracil) or dox added to the same regimen (PAF), while
'tamoxifen-responsive' patients were randomised to the same
two regimens in addition to adjuvant tamoxifen treatment
(Fisher et al., 1989). Dox contributed significantly to the
efficacy of adjuvant treatment in terms of disease-free and
overall survival in the patients untreated with tamoxifen,
while no effect of the addition of dox could be seen in
tamoxifen treated patients (Fisher et al., 1989). In a subse-
quent study the NSABP group has demonstrated that 2
months of adjuvant treatment with dox-cyclophosphamide
was as effective as 6 months of CMF (Fisher et al., 1990).
According to these studies dox seems to have activity in the
adjuvant setting as well as in metastatic disease and the
incidence of long-term toxicity seems to be low.
The present study differed from previous ones in including
a 2 weeks daily oral treatment with ftorafur, an analog to
fluorouracil in addition to cyclophosphamide and dox. This
may have contributed to the poor tolerance of the adjuvant
treatment, with 32% of the patients in the chemotherapy
arms discontinuing treatment mostly because of intolerable
gastrointestinal side-effects. The hematological side-effects
were also considerable, and tended to be more severe after
combination of radiotherapy and chemotherapy compared to
chemotherapy alone. That postoperative radiotherapy may
compromise the ability to deliver full-dose adjuvant chemo-
therapy has been reported previously (Sulkes et al., 1983).
In the previous adjuvant study in stage III at this depart-
ment with the VAC regimen only one out of 80 patients
discontinued treatment. The high toxicity of the present
regimen is probably at least partly attributable the oral
fluorouracil analogue, ftorafur. Despite the high incidence of
acute toxicity the long-term toxicity of the CAFt regimens
was low, with only one case of non-fatal cardiomyopathy.
Chemotherapy with the CAFt regimen seemed to increase the
frequency of pneumonitis after postoperative radiation
therapy. This occurred in spite of the fact that chemotherapy
was discontinued for a period of approximately 6 weeks
during which radiation was given. Dox is a radiosensitising
drug, which may increase the toxicity even when radiation
and chemotherapy are not delivered simultaneously (Cassady
et al., 1975; Mayer et al., 1976; Rosiello & Merrill, 1990).
Cyclophosphamide may also, albeit rarely, cause pulmonary
toxicity in its own right (Batist & Andrews, 1981; Ginsberg &
Comis, 1982; Patel et al., 1976; White et al., 1984). In this
study, however, dox related sensitising of radiation pneu-
monitis seems to be the more probable cause since the pul-
monary reaction was confined to the radiation field. Several
studies in lung cancer utilising the combination of dox and
radiation have also demonstrated the high pulmonary tox-
icity of this combination (Ohnoshi et al., 1986; Rosiello &
Merrill, 1990; Verschoore et al., 1987). Evidently special
attention has to be paid to the sequencing of radiation and
adjuvant chemotherapy as well as to the technical aspects of
radiotherapy when postoperative radiation is combined with
dox-containing adjuvant therapy in breast cancer.
As expected patients given postoperative radiotherapy
added to adjuvant chemotherapy had a lower (although not
statistically significantly) incidence of loco-regional failure,
which is in agreement with the findings of the Danish Breast
Cancer Study (Dombernowsky et al., 1988; Mouridsen &
Overgaard, 1990; Mouridsen et al., 1988). Although the effect
of postoperative radiotherapy on local recurrence did not
reach statistically significance, this may, at least partially,
have resulted from insufficient statistical power due to the
low overall loco-regional recurrence rate in this relatively
favourable subset of node positive breast cancer patients. The
effect of radiotherapy may also have been diminished by the
fact that adjuvant CAFt seemed to reduce the incidence of
local recurrence as effectively as radiation. A similar finding
has been reported in a M.D. Anderson study where the
incidence of local recurrence after FAC, radiotherapy and
the combination was 12%, 10% and 5% respectively, again
indicating that the best local control is achieved by combin-
ing optimal local therapy with adjuvant chemotherapy (Buz-
dar et al., 1990).
The poor tolerance of the adjuvant chemotherapy has the
effect ofdiminishing any impact ofchemotherapy on prognosis
since all patients were included in the analysis of treatment
outcome irrespective of dose reductions and discontinuation.
Despite this the combination of adjuvant chemotherapy and
radiotherapy increased relapse-free survival with marginal
statistical significant compared to radiotherapy alone. More-
over, the multivariate analysis indicated a significant effect of
adjuvant chemotherapy both on relapse-free and distant
relapse-free survival. The number of studied subjects was
probably too low for significant survival differences to
emerge. A few other studies have documented the effects of
combined postoperative radiation and adjuvant chemo- or
hormonotherapy. In an early trial by the Danish Breast
Cancer Group adjuvant chemotherapy with CMF was found
to improve survival even in addition to postoperative radia-
tion (Dombernowsky et al., 1988). In two later studies by the
DBCG it was found that addition of postoperative irradia-
tion to tamoxifen adjuvant therapy in postmenopausal and
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Figure 1 Relapse-free survival after adjuvant radiotherapy (RT),
chemotherapy (CT), radiotherapy +chemotherapy (CT + RT) or
radiotherapy + chemotherapy + tamoxifen CT + RT + Tam).
ISTAGE II BREAST CANCER ADJUVANT TRIAL 1175
CMF adjuvant chemotherapy in premenopausal patients, not
only reduced local recurrences, but even improved total sur-
vival in premenopausal patients (Dombernowsky et al., 1988;
Mouridsen & Overgaard, 1990; Mouridsen et al., 1988).
No overall effect of tamoxifen adjuvant treatment across
menopausal and receptor strata was found in this study when
tamoxifen was added to postoperative radiation and chemo-
therapy. Subgroup analysis, however, revealed a significantly
favorable effect on overall and recurrence-free survival as
well as distant metastases in the estrogen receptor positive
group, while the effect of tamoxifen in the receptor negative
group was unfavorable at marginal statistical significance.
The progesterone receptor content lacked the predictive value
of the estrogen receptor for the tamoxifen effect. No differ-
ential effect of tamoxifen according to age (below or above
50) was found in this study. Previous results of the combina-
tion of chemotherapy and tamoxifen adjuvant treatment are
conflicting. The most recent overview analysis indicated that
the effect of chemotherapy and tamoxifen may be indepen-
dent and additive in postmenopausal women, while the effect
of chemohormonal treatment in women below 50 years of
age remained unclear (EBCTCG, 1992). A few individual
trials have also reported findings relevant to the findings in
this study. Several studies have reported an improved
recurrence-free surival when tamoxifen is added to adjuvant
chemotherapy (Fisher et al., 1986; Marshall et al., 1987;
Mauriac et al., 1988), and one study including only receptor
positive patients (Mauriac et al., 1988) has reported a signi-
ficantly increased survival also. A few trials have also report-
ed statistically nonsignificant beneficial effects of the addition
of tamoxifen to adjuvant chemotherapy (Bianco et al., 1988;
Rutqvist et al., 1990; Senanayake, 1984; Taylor et al., 1989).
In contrast to this a Danish trial including pre- and peri-
menopausal patients found a significantly decreased survival
when tamoxifen was added to adjuvant CMF in interim
analysis, and the combination arm was therefore closed pre-
maturely (Dombernowsky et al., 1988). With longer follow-
up the statistical significance of this finding was, however,
lost. Subgroup analyses in the NSABP B-09 found evidence
of benefit of tamoxifen when added to melphalan-fluorouracil
only in estrogen and progesterone receptor positive patients,
although there was a suggestion of benefit also in receptor
negative older (>60 years) patients (Fisher et al., 1986). In
patients 49 years of age or younger, on the other hand,
tamoxifen had an adverse effect on overall survival when
added to chemotherapy (Fisher et al., 1986). In contrast to
this an ECOG trial comparing CMF with CMF + prednison
with CMF + prednison + tamoxifen reported a benefit in all
receptor subsets, which was most pronounced in patients
with estrogen receptor negative tumours (Taylor et al., 1989;
Tormey et al., 1990). The results ofour study tend to support
those of the NSABP study with respect to the adverse effect
on survival in estrogen receptor negative patients. In contrast
to the NSABP study we found no effect of patient age on
tamoxifen results. The lack of predictive value of the pro-
gesterone receptor in our study also contrast with the
findings in the NSABP study where the progesterone receptor
content was even more predictive for the benefit of tamoxifen
than the estrogen receptor. In the Mauriac study, on the
other hand, the benefit of tamoxifen added to CMF was
most pronounced in patients with tumours of high estrogen
receptor but low progesterone receptor content (Mauriac et
al., 1988). This agrees with the result of this study. The very
high mortality of patients with estrogen receptor positive
progesterone receptor negative tumours untreated with
tamoxifen compared to those given adjuvant hormono-
therapy probably explained the discrepant predictive effect of
estrogen and progesterone receptors on the effect of adjuvant
tamoxifen. The results concerning receptor levels and effect
of tamoxifen has to be interpreted with extreme caution,
since they emerged only in subgroup analysis of this rather
small trial and are dependent on a relatively small number of
events.
Thus, at present there are conflicting results on the effects
of combined tamoxifen and adjuvant chemotherapy in
various subsets of primary breast cancer. Although many
studies have found a beneficial effect and most studies have
failed to observe any adverse effect of tamoxifen when added
to adjuvant chemotherapy the findings of this study and
those of the NSABP B-09 trial raise some concern that
combined endocrine and cytotoxic adjuvant therapy might be
antagonistic at least in some patient subset.
Conclusions
Adjuvant treatment in stage II breast cancer with a regimen
consisting of oral ftorafur, and intravenous cyclophospha-
mide and dox was associated with considerable toxicity,
which led to discontinuations and dose reductions in almost
half of the treated patients.
Despite the low dose intensity adjuvant chemotherapy was
associated with a significantly improved relapse-free survival
and a tendency towards an increased distant relapse-free
survival in multivariate analysis.
The combination of dox containing adjuvant chemo-
therapy and postoperative radiation led to an increased inci-
dence of radiation pneumonitis and tended to increase the
incidence of hematological toxicity.
Tamoxifen adjuvant therapy when added to postoperative
radiation and chemotherapy did not result in any overall
improvement in local control, relapse free survival or overall
survival. In the subset of estrogen receptor positive tumours,
however, tamoxifen seemed to improve both relapse-free and
overall survival, while there might even have been an adverse
effect of tamoxifen in patients with estrogen receptor negative
tumours.
The study has been supported by Finska Lakaresallskapet and
Farmitalia Carlo Erbo, Scandinavia.
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